Eptifibatide-induced profound thrombocytopaenia: a rare complication

Area of Science:

• Hematology
• Pharmacology

Background:

• Drug-induced immune thrombocytopaenia (DITP) is a significant cause of low platelet counts, often triggered by medications.
• Common culprits include heparin and beta-lactam antibiotics, leading to autoantibody formation against the drug.
• Eptifibatide, an antiplatelet agent used in cardiac catheterization, is a rare but recognized cause of DITP.

Observation:

• A 64-year-old male presented with profound thrombocytopaenia and extensive skin bruising.
• The condition was identified as eptifibatide-induced DITP.
• Patients with DITP can range from asymptomatic to experiencing severe bleeding complications.

Findings:

• Eptifibatide administration led to a critical drop in platelet count.
• The patient received platelet transfusions as a therapeutic intervention.
• Platelet counts showed a rapid and positive response to the transfusions.

Implications:

• This case highlights eptifibatide as a potential cause of DITP, even in patients undergoing cardiac procedures.
• Prompt recognition and treatment, such as platelet transfusion, are crucial for managing severe eptifibatide-induced thrombocytopaenia.
• Understanding rare drug triggers for DITP is essential for clinical practice and patient safety.